OR WAIT 15 SECS
MilliporeSigma will collaborate with IPS and G-CON to offer end-to-end, turnkey, modular MAb manufacturing.
MilliporeSigma will collaborate with IPS-Integrated Project Services and G-CON Manufacturing to provide a 2000-L monoclonal antibody (mAb) facility and single-use process technology platform, the company announced in a Dec. 20, 2017 press release. The deal will extend MilliporeSigma's BioReliance End-to-End offering by integrating MilliporeSigma’s single-use process equipment, end-to-end process development capabilities, and cGMP manufacturing experience into the iCON facility design platform, which is a modular facility solution from IPS and G-CON announced in September 2017.
“Biologics are helping to fight some of the toughest diseases worldwide, and demand for these therapies continues to grow,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma, in the press release. “This collaboration is an innovative concept built upon MilliporeSigma’s years of experience in designing, constructing, and running cGMP biologics production, combined with the iCON facility, team, and design platform. It will decrease time-to-market and accelerate access to biologics to improve the lives of patients around the world.”
The integrated end-to-end offering will deliver a platform for fast and flexible deployment of 2000-L mAb production facilities. The hallmarks of the combined solution will include pre-fabricated cleanroom units, a structural platform based on cost-effective pre-engineered building delivery, bioprocess and single-use equipment expertise, and turnkey facilities capable of fast-track deployment.
This collaboration extends MilliporeSigma's BioReliance End-to-End offering, which is a suite of products and services that help biopharmaceutical companies accelerate the progression of molecules into the clinic and toward commercialization. The turnkey package includes process development, cGMP manufacturing, facility design, equipment for pilot plant production, process and equipment training, technology transfer, equipment qualification, and set-up for commercialization.
Related Content:Manufacturing, Monoclonal Antibodies | Manufacturing | News | Downstream Processing | Manufacturing Systems, Single-Use | Upstream Processing | Supplier News | Manufacturing Equipment, Biologics | Manufacturing, Drug Products | Manufacturing Equipment, Downstream Processing | Manufacturing Equipment, Upstream Processing | Manufacturing, Continuous Biologics Processing